No Data
No Data
Express News | Arrowhead Pharmaceuticals : Leerink Partners Cuts Target Price to $22 From $24
Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Goldman Sachs Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Cuts Target Price to $26
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80